• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    ACELYRIN Appoints Melanie Gloria as Chief Operating Officer

    1/11/22 7:45:00 AM ET
    $ABBV
    $ABT
    $HZNP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABBV alert in real time by email

    LOS ANGELES, Jan. 11, 2022 /PRNewswire/ -- ACELYRIN, INC., a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates, today announced the appointment of Melanie Gloria, BSN, as the company's chief operating officer (COO). In this role, Ms. Gloria will oversee business operations across the company.

    Melanie Gloria, ACELYRIN chief operations officer

    A former oncology nurse, Ms. Gloria has two decades' experience in the biotechnology industry having led a variety of research and development (R&D) functions. She is an experienced people leader who has managed large, diverse teams that achieved global approvals for blockbuster and life-saving therapies at Abbott (NYSE:ABT), AbbVie (NYSE:ABBV), and Horizon Therapeutics (NASDAQ:HZNP). Before joining ACELYRIN, she was senior vice president of development operations at Horizon. 

    "On behalf of the entire ACELYRIN leadership team, I am delighted to welcome Melanie as our chief operating officer. She joins us with a strong operational background and has led a variety of R&D functions in multiple therapeutic areas," said Shao-Lee Lin, M.D., Ph.D., co-founder and chief executive officer of ACELYRIN. "Her business operations, healthcare, and leadership experience will benefit ACELYRIN and our patients as we pursue our vision of bringing life-changing therapies to those with serious diseases."

    "I am thrilled to join ACELYRIN and this team of passionate colleagues as we work together to change patients' lives with innovative drug therapies," said Ms. Gloria. "I look forward to working with Shao-Lee, our board, and leadership team to build our organization and drive growth for our company and our investors. In addition to business strategy and operations and R&D, I'm passionate about mentoring and supporting others to achieve their highest aspirations. The culture of 'Courageous Caring' at ACELYRIN offers the ideal environment for this style of leadership."

    Ms. Gloria's leadership experience in business operations and clinical development spans multiple therapeutic areas, including cardiovascular, immunology, inflammation, ophthalmology, oncology, virology, and women's health. Throughout her career at Abbott, AbbVie, and Horizon, she has enabled global approvals of therapies including HUMIRA®, Viekera Pak®, Mavyret®, Skyrizi®, Rinvoq®, TEPEZZA®, and ORILISSA®.

    Ms. Gloria was named one of PharmaVOICE's 100 Most Inspiring People, received the Crain's Notable Women in Health Care award, and is a Healthcare Businesswomen's Association Luminary award recipient. She serves on the board of directors for Lake County Haven, an organization that empowers homeless women and their children to achieve permanent, independent living. She received a bachelor of science degree in nursing from the University of Illinois, Chicago.

    About ACELYRIN

    ACELYRIN, INC. is a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates and leveraging its expertise to rapidly advance these medicines to patients. For more information, please visit www.acelyrin.com.

    (PRNewsfoto/ACELYRIN)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/acelyrin-appoints-melanie-gloria-as-chief-operating-officer-301456543.html

    SOURCE ACELYRIN

    Get the next $ABBV alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ABBV
    $ABT
    $HZNP

    CompanyDatePrice TargetRatingAnalyst
    Abbott Laboratories
    $ABT
    7/18/2025$145.00Hold → Buy
    Jefferies
    Abbott Laboratories
    $ABT
    6/16/2025$143.00Market Perform
    Leerink Partners
    AbbVie Inc.
    $ABBV
    5/14/2025$205.00Buy → Neutral
    Citigroup
    AbbVie Inc.
    $ABBV
    4/22/2025$210.00Overweight
    Cantor Fitzgerald
    AbbVie Inc.
    $ABBV
    12/10/2024$191.00Neutral
    BofA Securities
    AbbVie Inc.
    $ABBV
    12/5/2024$180.00Outperform → Neutral
    Daiwa Securities
    AbbVie Inc.
    $ABBV
    11/22/2024$206.00Market Perform → Outperform
    Leerink Partners
    AbbVie Inc.
    $ABBV
    11/15/2024$205.00Outperform
    Wolfe Research
    More analyst ratings

    $ABBV
    $ABT
    $HZNP
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for VYALEV issued to ABBVIE INC

      Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

      10/18/24 4:38:13 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for VYALEV issued to ABBVIE INC

      Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form

      10/17/24 1:29:31 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for SKYRIZI issued to ABBVIE INC

      Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-7) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/18/2024. Application Category: BLA, Application Number: 761262, Application Classification:

      6/21/24 4:38:17 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABBV
    $ABT
    $HZNP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Abbvie Inc. claimed ownership of 7,048 shares (SEC Form 3)

      3 - AbbVie Inc. (0001551152) (Reporting)

      7/11/25 6:20:44 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Quaggin Susan E

      4 - AbbVie Inc. (0001551152) (Issuer)

      7/2/25 5:00:09 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Rapp Edward J

      4 - AbbVie Inc. (0001551152) (Issuer)

      7/2/25 5:00:10 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABBV
    $ABT
    $HZNP
    SEC Filings

    See more
    • Abbott Laboratories filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ABBOTT LABORATORIES (0000001800) (Filer)

      7/17/25 7:34:53 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by AbbVie Inc.

      SCHEDULE 13G/A - AbbVie Inc. (0001551152) (Subject)

      7/7/25 1:20:09 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - AbbVie Inc. (0001551152) (Filer)

      7/3/25 1:07:55 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABBV
    $ABT
    $HZNP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BOTOX® Cosmetic (onabotulinumtoxinA) Selects This Year's Entrepreneurs for The Confidence Project

      Select Business Owners Will Receive Access to Coaching, Mentorship, and Community During Exclusive 12-Week Virtual "Boostcamp"Additionally, 20 Entrepreneurs Will Each Receive a $20,000 Grant from BOTOX® CosmeticIRVINE, Calif., July 22, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), today announced the 2025 class of entrepreneurs who will participate in The Confidence Project: Empowering Women Entrepreneurs. This initiative, led by BOTOX® Cosmetic, is aimed at closing the Confidence Gap and accelerating business growth for select entrepreneurs from across the country. This year's participants were selected from a pool of applicants representing a wide range of indust

      7/22/25 8:00:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abbott Reports Second-Quarter 2025 Results

      Second-quarter reported sales growth of 7.4 percent; organic sales growth of 6.9 percent or 7.5 percent excluding COVID-19 testing-related sales1Second-quarter GAAP diluted EPS of $1.01; adjusted diluted EPS of $1.26Reported gross margin of 52.7 percent of sales; adjusted gross margin of 57.0 percent, which reflects a 100 basis point increaseReported operating margin of 18.4 percent of sales; adjusted operating margin of 22.9 percent, which reflects a 100 basis point increaseABBOTT PARK, Ill., July 17, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) today announced financial results for the second quarter ended June 30, 2025. Second-quarter sales increased 7.4 percent on a reported basis, 6.9 percen

      7/17/25 7:30:00 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Artificial Intelligence Revolutionizing Early Detection of Diabetic Retinopathy Creating a Multi-Billion Dollar Revenue Opportunity

      MarketNewsUpdates News Commentary NEW YORK, July 15, 2025 /PRNewswire/ -- Artificial Intelligence (AI) algorithms are revolutionizing the way retina images are analyzed for detecting conditions such as age-related macular degeneration (AMD) and diabetic retinopathy. These advanced algorithms often achieve diagnostic accuracies that equal or surpass human experts, especially in complex cases. This capability not only enhances diagnostic precision but also supports clinicians in delivering more effective treatment strategies.  AI systems that analyze retina images can spot early signs of diseases like age-related macular degeneration (AMD) and diabetic retinopathy. These conditions often devel

      7/15/25 8:45:00 AM ET
      $ABT
      $DXCM
      $IRTC
      $TNDM
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments

    $ABBV
    $ABT
    $HZNP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Abbott Labs upgraded by Jefferies with a new price target

      Jefferies upgraded Abbott Labs from Hold to Buy and set a new price target of $145.00

      7/18/25 7:54:43 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Abbott Labs with a new price target

      Leerink Partners initiated coverage of Abbott Labs with a rating of Market Perform and set a new price target of $143.00

      6/16/25 8:17:39 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie downgraded by Citigroup with a new price target

      Citigroup downgraded AbbVie from Buy to Neutral and set a new price target of $205.00

      5/14/25 8:54:15 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABBV
    $ABT
    $HZNP
    Leadership Updates

    Live Leadership Updates

    See more
    • Abbott and Real Madrid Kick Off Search to Empower Young Soccer Talent

      This summer, Abbott and Real Madrid are hosting tryouts across the U.S. to form the 'Abbott Dream Team'Tryout attendees will learn about health and sports nutrition, encouraging them to promote healthy habits and an active lifestyle in their communitiesEleven selected players will travel to Madrid, train at Real Madrid's world-class facilities, and be instructed by Real Madrid coachesAmerican soccer icon Clint Dempsey will mentor the athletes throughout their journeyABBOTT PARK, Ill., May 7, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) announced today the creation of the inaugural 'Abbott Dream Team.' The program will seek out talented soccer players from across the United States and give them a o

      5/7/25 9:00:00 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion

      Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company's commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His leadership will help expand awareness, accelerate growth, and strengthen market positioning of Cagent Vascular's proprietary serration balloon technology. Mr. Wilson brings many years of experience in the medical device industry, having held senior commercial leadership positions at Teleflex (NYSE:TFX) and Abbott (NYSE:ABT). With

      3/4/25 11:38:00 AM ET
      $ABT
      $TFX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors

      Richard A. Gonzalez to retire from the board of directors effective July 1, 2025NORTH CHICAGO, Ill., Feb. 14, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that its board of directors has unanimously elected chief executive officer (CEO) Robert A. Michael to assume the additional position of chairman, effective July 1, 2025. He will succeed Richard A. Gonzalez, who formerly served as AbbVie's CEO and has been chairman since the Company's formation in 2013. "I want to extend my heartfelt gratitude to Rick for his remarkable leadership and dedicated service," said Roxanne S. Austin, lead independent director. "The board and I have complete confidence in Rob, and we are fortunate to

      2/14/25 7:40:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABBV
    $ABT
    $HZNP
    Financials

    Live finance-specific insights

    See more
    • Abbott Reports Second-Quarter 2025 Results

      Second-quarter reported sales growth of 7.4 percent; organic sales growth of 6.9 percent or 7.5 percent excluding COVID-19 testing-related sales1Second-quarter GAAP diluted EPS of $1.01; adjusted diluted EPS of $1.26Reported gross margin of 52.7 percent of sales; adjusted gross margin of 57.0 percent, which reflects a 100 basis point increaseReported operating margin of 18.4 percent of sales; adjusted operating margin of 22.9 percent, which reflects a 100 basis point increaseABBOTT PARK, Ill., July 17, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) today announced financial results for the second quarter ended June 30, 2025. Second-quarter sales increased 7.4 percent on a reported basis, 6.9 percen

      7/17/25 7:30:00 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie to Host Second-Quarter 2025 Earnings Conference Call

      NORTH CHICAGO, Ill., June 30, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) will announce its second-quarter 2025 financial results on Thursday, July 31, 2025, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas –

      6/30/25 8:00:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abbott Hosts Conference Call for Second-Quarter Earnings

      ABBOTT PARK, Ill., June 26, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its second-quarter 2025 financial results on Thursday, July 17, before the market opens.  The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medica

      6/26/25 9:00:00 AM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABBV
    $ABT
    $HZNP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

      SC 13G/A - AbbVie Inc. (0001551152) (Subject)

      2/13/24 4:55:55 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

      SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

      2/13/24 4:55:58 PM ET
      $ABT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

      SC 13G/A - AbbVie Inc. (0001551152) (Subject)

      1/25/24 4:59:27 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care